Jiarun Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiarun Lai has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Funeng Jiang
Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics The Second Affiliated Hospital School of Medicine South China University of Technology Guangzhou China
1 shared publication- Huichan He
Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
1 shared publication Huijing Tan
Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics The Second Affiliated Hospital School of Medicine South China University of Technology Guangzhou China
1 shared publicationJian Chen
Guangdong Provincial Key Laboratory of Urology The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
1 shared publicationJinchuang Li
Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics The Second Affiliated Hospital School of Medicine South China University of Technology Guangzhou China
1 shared publicationJunchen Liu
Department of Integrative Biology and Pharmacology McGovern Medical School University of Texas Health Science Center Houston Texas USA
1 shared publication
Latest Publications
- Open Access
Depletion of Acetyl‐CoA Carboxylase 1 Facilitates Epithelial‐Mesenchymal Transition in Prostate Cancer Cells by Activating the MAPK/ERK Pathway
Hyperactivation of fatty acid biosynthesis holds promise as a targeted therapeutic strategy in prostate cancer (PCa). However, inhibiting these enzymes could potentially promote metastatic progression in various other cancers. Herein, we found that depletion of acetyl‐CoA carboxylase 1 (encoded by ACACA), the enzyme responsible for the first and rate‐limiting step of de novo fatty acid biosynthesis, facilitated epithelial‐mesenchymal transition (EMT) and migration of PCa cells. This finding was validated in vitro through cell migration assays and in vivo using a metastatic model established by tail vein injection of ACACA‐depleted cells into BALB/c nude mice. Additionally, depletion of ACACA activated the mitogen‐activated protein kinase (MAPK)/extracellular signal‐regulated protein kinases (ERK) pathway. Inhibition of the MAPK/ERK signaling pathway reduced EMT and migration in ACACA‐depleted cells. Our study is the first to indicate targeting ACACA induces an “unexpected” escape program through activation of the MAPK/ERK signaling pathway in PCa, ultimately leading to EMT and metastasis. Therefore, we strongly recommend that the potential adverse effects of targeting ACACA or its derived therapeutic agents must be given extreme attention, especially in MAPK‐related cancers.
Open AccessDepletion of Acetyl‐CoA Carboxylase 1 Facilitates Epithelial‐Mesenchymal Transition in Prostate Cancer Cells by Activating the MAPK/ERK Pathway
Hyperactivation of fatty acid biosynthesis holds promise as a targeted therapeutic strategy in prostate cancer (PCa). However, inhibiting these enzymes could potentially promote metastatic progression in various other cancers. Herein, we found that depletion of acetyl‐CoA carboxylase 1 (encoded by ACACA), the enzyme responsible for the first and rate‐limiting step of de novo fatty acid biosynthesis, facilitated epithelial‐mesenchymal transition (EMT) and migration of PCa cells. This finding was validated in vitro through cell migration assays and in vivo using a metastatic model established by tail vein injection of ACACA‐depleted cells into BALB/c nude mice. Additionally, depletion of ACACA activated the mitogen‐activated protein kinase (MAPK)/extracellular signal‐regulated protein kinases (ERK) pathway. Inhibition of the MAPK/ERK signaling pathway reduced EMT and migration in ACACA‐depleted cells. Our study is the first to indicate targeting ACACA induces an “unexpected” escape program through activation of the MAPK/ERK signaling pathway in PCa, ultimately leading to EMT and metastasis. Therefore, we strongly recommend that the potential adverse effects of targeting ACACA or its derived therapeutic agents must be given extreme attention, especially in MAPK‐related cancers.